Академический Документы
Профессиональный Документы
Культура Документы
witness
doctor in charge
Einwilligungserklrung
zur zentralen Datenerfassung und Dokumentation
In dem Bemhen, die Behandlungsmethoden stndig zu verbessern, hat sich unsere
Klinik mit anderen zusammengeschlossen, um mglichst viele und genaue medizinische Befunde aus den einzelnen Krankheitsverlufen zu dokumentieren, zu speichern und auszuwerten und eine rasche Zusammenarbeit der Kliniken untereinander
zu gewhrleisten. Um Verwechslungen, Doppelerfassungen und hnliches auszuschlieen, erfolgt diese Erfassung zusammen mit den Personalien (Name, Vorname,
Geburtsdatum, ggf. Geburtsname, Adresse). Ziel ist es, neue Erkenntnisse in der
Behandlung und der Ursachenforschung der Krankheit mglichst schnell vielen Patienten zugute kommen zu lassen, sowie die rztliche Nachsorgebetreuung zu verbessern. Die Daten werden an folgende Zentren bermittelt:
Deutsches Kinderkrebsregister
Institut fr Medizinische Biometrie,
Epidemiologie und Informatik der
Universitt Mainz
55101 Mainz
Regionales- / Landeskrebsregister:
_____________________________
_____________________________
_____________________________
_____________________________
Unterschriften:
Datum: ____________
____________________
____________________
Zeuge
____________________
gesprchsfhrender Arzt
11
AAssssoocciiaatteedd pprroojjeeccttss
1.1
It is evident from the brief overview of the cytogenetic profiles in GCTs provided in this protocol (see chapter
1.2.3) that a cyto- and molecular-genetic characterization is necessary in order to prospectively assign each
individual tumor to the appropriate biologic subgroup. This is particularly important, because the histologic
evaluation does not allow for distinguishing e.g. YST of the adult testis from YST of the infantile testis. The cut-off
between the infantile and the adult type can be estimated between an age from 5 to 15 years. However, the risk
of recurrence and therefore the clinical management differs between the two.
In addition, it is mandatory in certain situations to critically evaluate the constitutional karyotype, because GCTs at
certain sites may be associated with constitutional chromosomal aberrations. Therefore, a conventional
cytogenetic analysis of blood lymphocytes must be performed in each male patient with a mediastinal GCT and in
each female patient with a malignant ovarian GCT (see above). It can be assumed that the detection of
constitutional chromosomal aberrations will have a significant impact on the estimation of the risk of
metachronous GCTs and of prognosis (with respect to both survival and reproductive function after cure from
GCT) and therefore, on clinical management.
Cytogenetic analysis of blood lymphocytes
constitutional sex chromosomal abnormalities in:
is
recommended
for
the
detection
of
The studies aiming for the screening for potentially constitutional sex-chromosomal abnormalities will be
communicated to the treating physician. However, prior to communication, positive PCR based assays will be
confirmed with FISH technique. If both are positive for aberrant presence of Y-chromosomal material, the
physician will be informed. In this instance, the letter will include the explicit recommendation that evaluation of
blood lymphocytes is advisable and that a consultation of a board-certified human geneticist must be initiated.
1.1.1
The associated biologic studies aim for the evaluation of cytogenetic (e.g. CGH profiles, loss of heterocygosity
(LOH)) and molecular markers (e.g. microsatellite instability) that may be associated with clinical outcome and/or
resistance to therapy. If suitable (fresh-frozen) tissue is available, GCTs with mixed histology will be analyzed
after microdissection of the different histologic components in order to evaluate potential steps of tumor
progression. The associated molecular biologic studies will also address the question to what extent sex
chromosomal abnormalities at the sub-microscopic level contribute to the development of ovarian and mediastinal
GCTs.
1.1.2
The biologic studies will be coordinated by the MAKEI coordination center. Part of the analyses will be performed
by the research group at the Clinic of Pediatric Oncology, Hematology and Immunology in Dsseldorf (PD Dr.
D.T. Schneider). The tissue bank will be managed in Dsseldorf. Currently, cooperation with the U.S. Childrens
Oncology Group (COG) is planned. This cooperation will allow for performing the analyses focusing on a potential
clinical correlation of biologic markers in cooperation with the ongoing COG protocols on childhood GCTs.
Research groups from other institutions are encouraged to apply for the distribution of tissue samples for
complementary studies. The decision regarding these applications will be made by the MAKEI study coordinators
after review by the Ethics committee of the Heinrich-Heine-University. First priority will be given to applicants who
have received funding after peer review. In the past, samples have been distributed to collaborating institutions
from Germany, England, and the Netherlands.
1.1.3
Logistics
In every patient, blood ( 2 ml, anticoagulated with EDTA, at room temperature) has to be sent to the MAKEI
study center for comparison of constitutional DNA to tumor DNA from fresh frozen or archival (paraffin embedded)
samples. Otherwise, e.g. LOH and microsatellite instability studies and the studies on constitutional sexchromosomal aberrations are impossible.
In addition, the participating hospitals are strongly encouraged to contribute fresh-frozen tissue samples of each
surgical specimen to the MAKEI tissue bank, if sufficient tissue is left for histologic diagnosis. In Dsseldorf, the
presence of sufficient tumor tissue within the sample will be verified histologically. Tumor samples must be snapfrozen in liquid nitrogen and sent to the address mentioned below. Alternatively, the tissue samples may also be
sent to the tissue bank in Cologne (BioCase project of the GPOH Competence Network). After inclusion into the
tissue bank, the samples will be stored anonymously, and patient identifiers will be registered in the MAKEI
coordination office, only.
Distribution of fresh-frozen tissue samples:
BioCase Gewebebank
Prof. Dr. F. Berthold
Zentrum fr Pdiatrische Hmatologie
und Onkologie
Kinderklinik der Universitt
Joseph-Stelzmann-Str. 9
50931 Kln
GERMANY
Alternatively to:
MAKEI Studienleitung
z. Hd. Dr. Schnberger
Klinik fr Kinder-Onkologie,
-Hmatologie und -Immunologie
Heinrich-Heine-Universitt
Moorenstr. 5
40225 Dsseldorf
GERMANY
Specific recommendation regarding the use of the BioCase can be retrieved from the internet
(www.kinderkrebsinfo.de; www.kinderkrebsinfo.de/e1664/e1676/e1721/e7708/index_ger.html)
1.1.4
All patients and/or their parents will be informed about the purpose of including parts of surgical tissue samples
and blood for analysis of biologically and potentially also clinically relevant genetic aberrations. The patients have
to sign the declaration of consent (see appendix A) prior to genetic analysis. The forms can be copied form the
protocol or downloaded from the MAKEI homepage. A copy of the declaration has to be sent to the MAKEI
coordination center.
_______________________
Sorgeberechtigter/Vater
_______________________
Patient/in
_______________________
zustndiger Arzt/rztin